Eric B. Mosbrooker
Corporate Officer/Principal chez AVIDITY BIOSCIENCES, INC.
Fortune : - $ au 31/03/2024
Profil
Eric B.
Mosbrooker is currently the Director at the National Pharmaceutical Council and the Chief Strategy Officer at Avidity Biosciences, Inc. He previously held positions as the Senior Vice President-Orphan Business Unit & GM at Horizon Therapeutics Plc, the Chief Commercial Officer & Senior Vice President at Astellas Gene Therapies, Inc., the Chief Operations Officer at Cognoa, Inc., and the Senior Vice President-Americas & Asia Pacific at Raptor Pharmaceuticals, Inc. He also served as the Chief Commercial Officer at Origin Biosciences, Inc. Mr. Mosbrooker obtained his undergraduate degree from the University of Wisconsin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AVIDITY BIOSCIENCES INC
-.--% | 15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Eric B. Mosbrooker
| Sociétés | Poste | Début |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Corporate Officer/Principal | 05/01/2024 |
National Pharmaceutical Council
 National Pharmaceutical Council Miscellaneous Commercial ServicesCommercial Services The National Pharmaceutical Council operates as a not for profit organization. It specializes in research development, information dissemination, education, and communication of information to patients. The company was founded in 1953 and is headquartered in Washington, DC. | Director/Board Member | 06/03/2018 |
Anciens postes connus de Eric B. Mosbrooker
| Sociétés | Poste | Fin |
|---|---|---|
Cognoa, Inc.
 Cognoa, Inc. Medical/Nursing ServicesHealth Services Cognoa, Inc. offers a mobile application and proprietary algorithm to enable early detection of autism. The firm is a consumer healthcare company that?s changing how parents assess and support their child?s development. The company was founded by Dennis Wall and Brent Vaughan and is headquartered in Palo Alto, CA. | Chief Operating Officer | 01/02/2023 |
| AUDENTES THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2021 |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Chief Operating Officer | 01/12/2018 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | 01/04/2018 |
Raptor Pharmaceuticals, Inc.
 Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Corporate Officer/Principal | 01/11/2016 |
Formation de Eric B. Mosbrooker
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
National Pharmaceutical Council
National Pharmaceutical Council Miscellaneous Commercial ServicesCommercial Services The National Pharmaceutical Council operates as a not for profit organization. It specializes in research development, information dissemination, education, and communication of information to patients. The company was founded in 1953 and is headquartered in Washington, DC. | Commercial Services |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Cognoa, Inc.
Cognoa, Inc. Medical/Nursing ServicesHealth Services Cognoa, Inc. offers a mobile application and proprietary algorithm to enable early detection of autism. The firm is a consumer healthcare company that?s changing how parents assess and support their child?s development. The company was founded by Dennis Wall and Brent Vaughan and is headquartered in Palo Alto, CA. | Health Services |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Health Technology |
